Gamma-linolenic acid-mediated inflammatory pathway modulation (GLA-mediated inflammatory pathway modulation)

The entry "Inflammatory pathway modulation via gamma-linolenic acid delivery" does not refer to a single canonical therapeutic target such as a receptor or enzyme. Instead, it describes the **modulation of inflammatory pathways through administration of gamma-linolenic acid (GLA)**—an omega‑6 polyunsaturated fatty acid found in certain plant oils. **Mechanistically**, GLA is converted in the body into dihomo-gamma-linolenic acid (DGLA), which can be incorporated into cell membranes and released upon stimulation. DGLA then competes with arachidonic acid for cyclooxygenase and lipoxygenase enzymes. This competition results in increased production of anti-inflammatory eicosanoids like prostaglandins E1 and thromboxane A1 while reducing pro-inflammatory mediators such as leukotriene B4. **Biologically**, this leads to reduced expression or secretion of key inflammatory mediators including interleukin 1-beta, inducible nitric oxide synthase, cyclooxygenase 2, soluble intercellular adhesion molecule 1 (sICAM‑1), monocyte chemoattractant protein 1 (MCP‑1), RANTES/CCL5 chemokine, and IL‑6 by immune cells exposed to pro-inflammatory stimuli like LPS or TNF-alpha. The effect is partly mediated by inhibition/inactivation of transcription factors NF-kappaB and AP‑1 through suppression of oxidative stress–related signal transduction pathways involving ERK/JNK kinases. **Clinically**, oral supplementation with GLA has been shown to reduce joint pain/swelling in rheumatoid arthritis patients—sometimes decreasing reliance on NSAIDs/corticosteroids—and may have potential benefits for other chronic inflammatory conditions. There are also preclinical data suggesting possible anticancer effects via direct cytotoxicity on tumor cells and inhibition of angiogenesis/apoptosis induction. However, because this entry refers broadly to an entire metabolic/signaling process rather than an individual molecular target suitable for drug development screening or structure-based design efforts—and because it lacks specificity regarding any one protein/receptor/enzyme—it should not be considered a canonical therapeutic target.

Other names

Gamma-linolenic acid (GLA) anti-inflammatory mechanismGLA-induced inflammation modulationGLA pathwayGamma-linolenic acid signaling

Conversion of GLA to dihomo-gamma-linolenic acid (DGLA), which competes with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, leading to production of anti-inflammatory eicosanoids such as prostaglandin E1.